Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Retrieved on:
Tuesday, February 2, 2021
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Kidney diseases, Nephrology, Organic compounds, Glomerulosclerosis, Focal segmental glomerulosclerosis, IgA nephropathy, Irbesartan, Angiotensin II receptor blocker, Proteinuria, the DUPLEX Study, Focal Segmental Glomerulosclerosis, Sparsentan, Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment.
Key Points:
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment.
- Today, we are very pleased to announce interim proteinuria results from the ongoing DUPLEX Study that demonstrate treatment with sparsentan can lead to significantly greater reductions in proteinuria compared to current standard of care.
- Travere is providing limited data from the interim analyses to maintain trial integrity in the ongoing study.
- In the DUPLEX Study, a total of 371 patients were randomized 1:1 to receive either sparsentan or irbesartan, the active control.